Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer

Inclusion Criteria: * Locally advanced carcinoma of the pancreas * Arterial invasion or encasement * Invasion/encasement of the portomesenteric veins * Patients who have been previously denied operation * Obstructive jaundice must be drained with a polyethylene biliary stent or surgical bypass prior to beginning treatment. * White blood cell count \> 3500 per ml and platelet count \> 100,000 per ml * Serum creatinine ≤ 1.5 mg/dl * Bilirubin ≤ 1.5 * ECOG performance status \< 2 Exclusion Criteria: * Prior chemotherapy, radiotherapy, or investigational agents for pancreatic cancer * Evidence of distant metastasis or malignant lymphadenopathy * Concurrent malignancies * History of allergic reactions to celecoxib or to sulfa drugs * No non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, magnesium or aluminum containing antacids, fluconazole or lithium may be administered within 5 days of study entry, during the study and for the 30 days following the completion of all study treatments. * Pregnant women and lactating women * Uncontrolled or serious intercurrent illness * HIV-positive patients receiving combination antiretroviral therapy